JP Morgan Chase
EDIT icon

JP Morgan Chase’s Editas Medicine EDIT Stock Holding History

JP Morgan Chase’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.34M Buy
1,947,384
+1,164,280
+149% +$2.46M ﹤0.01% 3451
2025
Q4 		$1.61M Sell
783,104
-37,563
-5% -$108K ﹤0.01% 4261
2025
Q3 		$2.85M Sell
820,667
-245,055
-23% -$684K ﹤0.01% 3810
2025
Q2 		$2.34M Buy
1,065,722
+140,916
+15% +$231K ﹤0.01% 3790
2025
Q1 		$1.07M Buy
924,806
+137,207
+17% +$202K ﹤0.01% 4294
2024
Q4 		$1M Buy
787,599
+16,419
+2% +$41.8K ﹤0.01% 4635
2024
Q3 		$2.63M Sell
771,180
-28,018
-4% -$122K ﹤0.01% 3770
2024
Q2 		$3.73M Sell
799,198
-182,323
-19% -$1.03M ﹤0.01% 3271
2024
Q1 		$7.28M Sell
981,521
-69,486
-7% -$577K ﹤0.01% 2767
2023
Q4 		$10.6M Sell
1,051,007
-9,284
-0.9% -$81.5K ﹤0.01% 2405
2023
Q3 		$8.27M Sell
1,060,291
-64,214
-6% -$551K ﹤0.01% 2415
2023
Q2 		$9.25M Sell
1,124,505
-8,446
-0.7% -$73.6K ﹤0.01% 2354
2023
Q1 		$8.21M Sell
1,132,951
-49,703
-4% -$442K ﹤0.01% 2446
2022
Q4 		$10.5M Buy
1,182,654
+19,328
+2% +$212K ﹤0.01% 2207
2022
Q3 		$14.2M Sell
1,163,326
-37,275
-3% -$581K ﹤0.01% 1863
2022
Q2 		$14.2M Sell
1,200,601
-55,960
-4% -$750K ﹤0.01% 1894
2022
Q1 		$23.9M Sell
1,256,561
-207,502
-14% -$3.86M ﹤0.01% 1638
2021
Q4 		$38.9M Buy
1,464,063
+336,305
+30% +$11.6M ﹤0.01% 1347
2021
Q3 		$46.3M Buy
1,127,758
+25,311
+2% +$1.39M 0.01% 1218
2021
Q2 		$62.4M Buy
1,102,447
+136,978
+14% +$5.06M 0.01% 1109
2021
Q1 		$40.5M Buy
965,469
+378,786
+65% +$21.6M 0.01% 1261
2020
Q4 		$41.1M Buy
586,683
+124,898
+27% +$5.13M 0.01% 1167
2020
Q3 		$13.4M Buy
461,785
+99,356
+27% +$3.24M ﹤0.01% 1797
2020
Q2 		$10.7M Buy
362,429
+102,290
+39% +$2.67M ﹤0.01% 1845
2020
Q1 		$5.16M Buy
260,139
+150,764
+138% +$3.8M ﹤0.01% 2234
2019
Q4 		$3.24M Buy
109,375
+92,705
+556% +$2.32M ﹤0.01% 3031
2019
Q3 		$379K Buy
16,670
+3,038
+22% +$75.3K ﹤0.01% 4305
2019
Q2 		$319K Buy
13,632
+2,402
+21% +$57.3K ﹤0.01% 4445
2019
Q1 		$275K Sell
11,230
-31,247
-74% -$707K ﹤0.01% 4482
2018
Q4 		$967K Sell
42,477
-9,265
-18% -$252K ﹤0.01% 3765
2018
Q3 		$1.65M Buy
51,742
+1,113
+2% +$36K ﹤0.01% 3595
2018
Q2 		$1.81M Sell
50,629
-571
-1% -$20.2K ﹤0.01% 3482
2018
Q1 		$1.7M Buy
51,200
+43,521
+567% +$1.55M ﹤0.01% 3372
2017
Q4 		$236K Buy
7,679
+7,429
+2,972% +$187K ﹤0.01% 4358
2017
Q3 		$6K Hold
250
– – ﹤0.01% 4778
2017
Q2 		$4K Hold
250
– – ﹤0.01% 4777
2017
Q1 		$6K Buy
+250
New +$5.18K ﹤0.01% 4874
2016
Q4 		– Sell
-1,812
Closed -$24K – 5023
2016
Q3 		$24K Buy
+1,812
New +$37.1K ﹤0.01% 4165
2016
Q2 		– Sell
-72,500
Closed -$2.5M – 4819
2016
Q1 		$2.5M Buy
+72,500
New +$1.91M ﹤0.01% 2583

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

JP Morgan Chase's EDIT Position: Q1 2026 in Review

JP Morgan Chase increased its Editas Medicine (EDIT) stake by 149% in Q1 2026, buying an estimated $2.46M and bringing the position to 1,947,384 shares worth $4.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3451.

JP Morgan Chase first reported a position in EDIT in Q1 2016 and has held it in 39 quarters since. The position peaked at $62.4M in Q2 2021. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • JP Morgan Chase held 1,947,384 shares of Editas Medicine worth $4.34M as of Q1 2026.
  • JP Morgan Chase bought 1,164,280 Editas Medicine shares in Q1 2026, an estimated $2.46M.
  • Editas Medicine made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3451 holding.
  • JP Morgan Chase first reported a position in Editas Medicine in Q1 2016 and has held it in 39 quarters since.
  • JP Morgan Chase's Editas Medicine position peaked at $62.4M in Q2 2021.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.